Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. For our social media and community guidelines, including information on how to report adverse events, please visit www.eigerbio.com/social-media-guidelines/